# Beam Therapeutics Inc.

Summary updated: 2026-10-02T12:12:57.824776Z
Canonical: https://finbar.com/research/companies/beam-therapeutics-inc

## Overview

Beam Therapeutics Inc. is a clinical-stage biotechnology company developing precision genetic medicines using a proprietary base-editing platform, designed to make targeted single-letter DNA changes without double-strand breaks. Its development work includes genetic diseases such as sickle cell disease, beta-thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type 1a. The company’s stated vision is to provide lifelong cures for people with serious diseases. [1](https://app.finbar.com/go?id=P145836616)[2](https://app.finbar.com/go?id=P145836619)[3](https://app.finbar.com/go?id=P145836333)[4](https://beamtx.com/about-us/)

Beam is based in Cambridge, Massachusetts, and also has a manufacturing facility in Durham, North Carolina. For FY2025, it reported $139.743 million in license and collaboration revenue; it reported no product-sales revenue to date in its Q2 2026 filing. Revenue for the six months ended June 30, 2026 was $32.228 million. A third-party source estimates 511 employees at year-end 2025. [5](https://app.finbar.com/go?id=T12184205)[6](https://app.finbar.com/go?id=P145836693)[7](https://app.finbar.com/go?id=T16688336)[8](https://beamtx.com/locations/cambridge/)[9](https://beamtx.com/locations/research-triangle-park/)[10](https://stockanalysis.com/stocks/beam/employees/)
[1](https://app.finbar.com/go?id=P145836616)[2](https://app.finbar.com/go?id=P145836619)[3](https://app.finbar.com/go?id=P145836333)[5](https://app.finbar.com/go?id=T12184205)[6](https://app.finbar.com/go?id=P145836693)[7](https://app.finbar.com/go?id=T16688336)[4](https://beamtx.com/about-us/)[8](https://beamtx.com/locations/cambridge/)[9](https://beamtx.com/locations/research-triangle-park/)[10](https://stockanalysis.com/stocks/beam/employees/)

## Products & services

Beam Therapeutics’ investigational products include **risto-cel (ristoglogene autogetemcel; formerly BEAM-101)**, an autologous hematopoietic stem-cell therapy for sickle cell disease. Its base edits are designed to mimic naturally occurring variants associated with hereditary persistence of fetal hemoglobin. The Phase 1/2 BEACON trial completed dosing of adult and adolescent patients; the company said a biologics license application could be submitted as early as year-end 2026. [11](https://app.finbar.com/go?id=P145836621)[12](https://app.finbar.com/go?id=P145836623)[13](https://app.finbar.com/go?id=P145836634)

**BEAM-302** is a liver-targeted lipid nanoparticle (LNP) base-editing candidate intended to correct the SERPINA1 E342K/PiZ mutation that causes alpha-1 antitrypsin deficiency. Its Phase 1/2 study was ongoing, and a global pivotal cohort began dosing in July 2026. **BEAM-301** uses liver-targeted LNP delivery to correct the G6PC R83C mutation associated with glycogen storage disease Ia; its Phase 1/2 trial was dosing patients in cohort two. **BEAM-304** is a liver-targeted candidate designed to correct disease-causing PAH mutations in phenylketonuria; after FDA clearance of its investigational new drug application in June 2026, the company began start-up for a Phase 1/2 trial initially focused on the R408W mutation. [14](https://app.finbar.com/go?id=P145836641)[15](https://app.finbar.com/go?id=P145836149)[16](https://app.finbar.com/go?id=P145836151)[17](https://app.finbar.com/go?id=P145836669)[18](https://app.finbar.com/go?id=P145836670)[19](https://app.finbar.com/go?id=P145836665)[20](https://app.finbar.com/go?id=P145836667)

**BEAM-103** is an anti-CD117 monoclonal antibody being studied as a non-genotoxic conditioning agent to support potential ex vivo and in vivo sickle cell disease therapies; it is an enabling candidate rather than a gene-editing treatment. Beam’s base-editing platform uses CRISPR-guided editing designed to modify individual DNA bases without making double-stranded DNA breaks. Its LNP platform delivers base-editor mRNA and guide RNA for in vivo editing. The company reported no product-sales revenue to date, and its disclosures did not identify a separate productized service offering. [21](https://app.finbar.com/go?id=P145836174)[1](https://app.finbar.com/go?id=P145836616)[22](https://app.finbar.com/go?id=P145836639)[6](https://app.finbar.com/go?id=P145836693)
[11](https://app.finbar.com/go?id=P145836621)[12](https://app.finbar.com/go?id=P145836623)[13](https://app.finbar.com/go?id=P145836634)[14](https://app.finbar.com/go?id=P145836641)[15](https://app.finbar.com/go?id=P145836149)[16](https://app.finbar.com/go?id=P145836151)[17](https://app.finbar.com/go?id=P145836669)[18](https://app.finbar.com/go?id=P145836670)[19](https://app.finbar.com/go?id=P145836665)[20](https://app.finbar.com/go?id=P145836667)[21](https://app.finbar.com/go?id=P145836174)[1](https://app.finbar.com/go?id=P145836616)[22](https://app.finbar.com/go?id=P145836639)[6](https://app.finbar.com/go?id=P145836693)

## Geographic presence

Beam Therapeutics’ disclosed operating footprint is in the United States. Its principal executive office is in Cambridge, Massachusetts; the 2025 Form 10-K reports about 130,258 square feet of office and laboratory space there. The company also has a 100,000-square-foot manufacturing facility in Research Triangle Park, North Carolina, for manufacturing capabilities supporting its programs. [23](https://app.finbar.com/go?id=P145836317)[24](https://app.finbar.com/go?id=P85517912)[25](https://app.finbar.com/go?id=P15517205) Beam identifies Cambridge as its biotech hub and Research Triangle Park as its manufacturing-facility location. [8](https://beamtx.com/locations/cambridge/)[9](https://beamtx.com/locations/research-triangle-park/)

Beam reports one operating segment and describes its operations as exclusively in the United States; the cited disclosures do not provide revenue by country or region. [26](https://app.finbar.com/go?id=P24878888)[27](https://app.finbar.com/go?id=P32440740) The 2025 Form 10-K reports 511 full-time team members, with counts by job function, but does not give employee numbers by location or geography. [28](https://app.finbar.com/go?id=P27024050)
[23](https://app.finbar.com/go?id=P145836317)[24](https://app.finbar.com/go?id=P85517912)[25](https://app.finbar.com/go?id=P15517205)[8](https://beamtx.com/locations/cambridge/)[9](https://beamtx.com/locations/research-triangle-park/)[26](https://app.finbar.com/go?id=P24878888)[27](https://app.finbar.com/go?id=P32440740)[28](https://app.finbar.com/go?id=P27024050)[8](https://beamtx.com/locations/cambridge/)[9](https://beamtx.com/locations/research-triangle-park/)

## Business segments

Beam Therapeutics reports a single operating and reportable segment: its consolidated business. It does not report separate segments for individual programs, therapeutic areas, or delivery approaches. The sole segment therefore represents 100% of reported operations, but the company does not disclose revenue percentages by program or other business category. [29](https://app.finbar.com/go?id=P16613045)[26](https://app.finbar.com/go?id=P24878888)

The company’s segment activities encompass development of precision genetic medicines using its base-editing platform, including ex vivo and in vivo approaches. These are descriptions of its platform and activities, not separately reported segments. [30](https://app.finbar.com/go?id=P101320203)
[29](https://app.finbar.com/go?id=P16613045)[26](https://app.finbar.com/go?id=P24878888)[30](https://app.finbar.com/go?id=P101320203)

## Company history

Beam Therapeutics was incorporated and began operations in January 2017. Its public launch followed in May 2018, when co-founders David R. Liu, Feng Zhang, and J. Keith Joung announced the company’s focus on base-editing technology. [31](https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm) [32](https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create)

Beam went public on Nasdaq in February 2020. In 2021, it acquired Guide Therapeutics to add delivery technology and a lipid library. In 2022, it entered a multi-target in-vivo base-editing research collaboration with Pfizer and helped launch Orbital Therapeutics to develop RNA medicines. [33](https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm) [34](https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23) [35](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research) [36](https://app.finbar.com/go?id=P5243303)

The company moved base-editing programs into clinical testing in 2023: it reported first-patient dosing in the BEAM-201 trial that September and in the BEAM-101 sickle-cell trial in the fourth quarter. In 2024, it reported first-patient dosing in the BEAM-302 trial for alpha-1 antitrypsin deficiency. [37](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial) [38](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/) [39](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/)
[31](https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm)[32](https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create)[33](https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm)[34](https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23)[35](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research)[36](https://app.finbar.com/go?id=P5243303)[37](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial)[38](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/)[39](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/)[31](https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm)[32](https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create)[33](https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm)[34](https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23)[35](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research)[37](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial)[38](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/)[39](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/)

## Sources

1. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836616)
2. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836619)
3. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836333)
4. [beamtx.com](https://beamtx.com/about-us/)
5. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T12184205)
6. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836693)
7. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16688336)
8. [beamtx.com](https://beamtx.com/locations/cambridge/)
9. [beamtx.com](https://beamtx.com/locations/research-triangle-park/)
10. [stockanalysis.com](https://stockanalysis.com/stocks/beam/employees/)
11. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836621)
12. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836623)
13. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836634)
14. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836641)
15. [Beam Therapeutics Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P145836149)
16. [Beam Therapeutics Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P145836151)
17. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836669)
18. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836670)
19. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836665)
20. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836667)
21. [Beam Therapeutics Inc. — Press release (2026 Q 2)](https://app.finbar.com/go?id=P145836174)
22. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836639)
23. [Beam Therapeutics Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P145836317)
24. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P85517912)
25. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P15517205)
26. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P24878888)
27. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P32440740)
28. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P27024050)
29. [Beam Therapeutics Inc. — Full financial report (2026 Q 1)](https://app.finbar.com/go?id=P16613045)
30. [Beam Therapeutics Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P101320203)
31. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm)
32. [www.businesswire.com](https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create)
33. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm)
34. [www.nasdaq.com](https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23)
35. [www.pfizer.com](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research)
36. [Beam Therapeutics Inc. — Full financial report (2022 Y)](https://app.finbar.com/go?id=P5243303)
37. [investors.beamtx.com](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial)
38. [investors.beamtx.com](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/)
39. [investors.beamtx.com](https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.